Search clinical trials for: GW685698X & GW642444M

Total 77 results

GlaxoSmithKline

Completed

Study to Assess GW642444 in Asthma Patients

Pulmonary Disease, Chronic Obstructive

Australia, New Zealand
GlaxoSmithKline

Completed

A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Sweden, Norway
GlaxoSmithKline

Completed

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects

Asthma

Australia
GlaxoSmithKline

Completed

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

Asthma

United States, Australia, Germany, Russian Federation, Bulgaria, Canada, Chile, Peru, Philippines, South Africa, Thailand, Mexico, Israel, Ukraine, New Zealand, Croatia
GlaxoSmithKline

Completed

Safety, Blood Levels and Effects of GW642444

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry

Asthma

Korea, Republic of, China, Philippines
GlaxoSmithKline

Completed

Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.

Asthma

New Zealand
GlaxoSmithKline

Completed

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis

Vasomotor Rhinitis | Rhinitis, Vasomotor

United States, Romania, Czechia, Canada, Germany, Puerto Rico, Norway
GlaxoSmithKline

Completed

A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

Rhinitis, Allergic, Perennial

United States, Canada
GlaxoSmithKline

Completed

Study In Adults And Adolescents With Seasonal Allergic Rhinitis.

Rhinitis, Allergic, Seasonal

Netherlands, Estonia, Russian Federation, Sweden, Latvia, Lithuania
GlaxoSmithKline

Completed

Seasonal Allergic Rhinitis In Pediatric Subjects

Rhinitis, Allergic, Perennial

United States
GlaxoSmithKline

Completed

Study Of Adults And Adolescents With Vasomotor Rhinitis

Rhinitis, Vasomotor

United States, Germany, Canada, Czechia, Romania, Norway
GlaxoSmithKline

Completed

Perennial Allergic Rhinitis Study In Pediatric Subjects

Rhinitis, Allergic, Perennial

United States, Argentina, Slovakia, Finland, Chile, Mexico, Italy
GlaxoSmithKline

Completed

Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma

Asthma

United States
GlaxoSmithKline

Completed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Estonia, Canada, Chile, Germany, Peru, Philippines, Mexico, Korea, Republic of, Denmark, Russian Federation, Poland, Slovakia
GlaxoSmithKline

Completed

Repeat Dose GW685698X With Magnesium Stearate, Excipient Bridging Study, In Healthy Volunteers

Asthma

Australia
GlaxoSmithKline

Completed

A Study of GW685698X in Healthy Japanese Male Subjects

Asthma

Japan
GlaxoSmithKline

Completed

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)

Rhinitis, Allergic, Seasonal

United States
GlaxoSmithKline

Completed

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

Rhinitis, Allergic, Seasonal

United States
GlaxoSmithKline

Completed

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics

Rhinitis, Allergic, Perennial

United States
GlaxoSmithKline

Completed

Study Of Perennial Allergic Rhinitis

Rhinitis, Allergic, Seasonal
GlaxoSmithKline

Completed

Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.

Asthma

United States, Argentina, Poland, Russian Federation, Belgium, Canada, Chile, France, Germany, Korea, Republic of, Netherlands, Peru, Philippines, South Africa, Sweden, Thailand
GlaxoSmithKline

Completed

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

Asthma

United States
GlaxoSmithKline

Completed

A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function

Asthma
GlaxoSmithKline

Completed

Phase I Study of GW642444M in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.

Asthma

Korea, Republic of, China, Philippines
GlaxoSmithKline

Completed

A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

Australia, New Zealand
GlaxoSmithKline

Completed

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Asthma

Germany, Romania, Bulgaria, Chile, Russian Federation, South Africa, Estonia, Italy, Mexico, Greece, Hungary, Croatia, Brazil
Queen's University
GlaxoSmithKline

Completed

Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD

COPD

Canada
GlaxoSmithKline

Completed

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

Asthma

United States, Australia, Germany, Bulgaria, Canada, Chile, France, Peru, Russian Federation, South Africa, Mexico, Estonia, Netherlands, Thailand, Poland, Czechia
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Germany, Estonia, Chile, Netherlands, Peru, South Africa, Sweden, Mexico, United Kingdom, Italy, Philippines, Canada
GlaxoSmithKline

Completed

A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Australia, Romania, Bulgaria, Germany, Netherlands, New Zealand
GlaxoSmithKline

Completed

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Argentina, Germany, Spain, South Africa, Mexico, Peru, Netherlands, Canada, United Kingdom, Denmark, Chile, Italy, Sweden
GlaxoSmithKline

Completed

A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.

Pulmonary Disease, Chronic Obstructive

Netherlands
GlaxoSmithKline

Completed

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.

Asthma

United States, Germany, Estonia, Canada, Korea, Republic of, South Africa, Mexico, Greece, Russian Federation, Philippines, Slovakia, Poland, Romania
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, United States, Bulgaria, Estonia, United Kingdom
GlaxoSmithKline

Completed

Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray

Rhinitis, Allergic, Perennial and Seasonal

Denmark
GlaxoSmithKline

Completed

Long Term Safety Of GW685698X Via Nasal Biopsy

Rhinitis, Allergic, Perennial

Netherlands, Belgium
GlaxoSmithKline

Completed

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

Asthma

United States, Germany, Poland, Russian Federation, Bulgaria, Estonia, Canada, France, Korea, Republic of, Peru, Philippines, Mexico, Sweden, Slovakia
GlaxoSmithKline

Completed

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia

Search clinical trials for: GW685698X & GW642444M

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations